SOUTH SAN FRANCISCO, California, 21 May 2026
Veracyte, Inc. announced that major Phase III clinical trial results involving its Prosigna Breast and Decipher Prostate genomic tests will be presented at the ASCO Annual Meeting 2026 in Chicago. The data from the landmark OPTIMA and ENZAMET studies are expected to provide strong evidence supporting the use of genomic testing to guide chemotherapy and treatment intensification decisions in both breast and prostate cancer. The company believes the findings could significantly reshape precision oncology by helping clinicians better personalize cancer treatment while reducing unnecessary therapy exposure and treatment-related toxicity.
OPTIMA Trial Supports Prosigna-Guided Chemotherapy Decisions
The Phase III OPTIMA study evaluated how Veracyte’s Prosigna Breast Risk of Recurrence test can guide chemotherapy decisions in patients with high-risk, hormone receptor-positive, HER2-negative early breast cancer. Led by University College London and supported by the UK National Institute for Health Research, the trial enrolled more than 4,400 patients in a prospective randomized design.
The study was specifically designed to identify which patients are likely to benefit from chemotherapy and which patients may safely avoid treatment and its associated long-term side effects. According to Veracyte, the findings are expected to provide Level 1A evidence supporting Prosigna-guided treatment strategies. The oral presentation will be delivered by Dr. Robert Stein during the breast cancer session at ASCO 2026.
Company executives stated that the results represent a major milestone for precision breast oncology and may significantly influence future clinical practice guidelines. By integrating genomic profiling into treatment planning, clinicians could potentially reduce overtreatment while maintaining strong patient outcomes.
ENZAMET Study Highlights Personalized Prostate Cancer Care
Advertisement
Additional ASCO presentations will feature data from the international ENZAMET trial evaluating Veracyte’s Decipher Prostate Genomic Classifier in metastatic hormone-sensitive prostate cancer. The analysis assessed the test’s ability to predict which patients are most likely to benefit from adding docetaxel chemotherapy to androgen deprivation therapy and enzalutamide.
The results suggest that Decipher can help identify patients who may require intensified triplet therapy while allowing lower-risk patients to avoid unnecessary chemotherapy-related toxicity. Veracyte said the findings support a more individualized approach to metastatic prostate cancer management and could improve treatment selection decisions in routine clinical practice.
Additional prostate cancer studies being presented at ASCO will explore transcriptomic risk stratification, genomic classifier-driven NCCN risk reclassification, and real-world treatment outcomes in elderly prostate cancer populations. These studies further expand the evidence base supporting genomic testing in precision oncology.
Genomic Diagnostics Continue Expanding in Oncology
Veracyte continues strengthening its position as a major player in molecular cancer diagnostics through a growing portfolio of genomic and AI-driven oncology tools. The company’s commercial test portfolio includes Prosigna Breast, Decipher Prostate, Decipher Bladder, Afirma Genomic Sequencing Classifier, and the TrueMRD Monitoring Test for muscle-invasive bladder cancer.
Executives stated that the ASCO presentations highlight how genomic testing is increasingly helping physicians align treatment intensity with individual patient biology across multiple cancer types. As healthcare systems move toward precision medicine and value-based care, genomic classifiers are becoming increasingly important for improving patient outcomes while reducing unnecessary treatment costs and toxicity burden.
The company will also showcase additional bladder cancer and AI-driven oncology research during poster sessions throughout the ASCO 2026 meeting.
Source: Veracyte press release
